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Abstract
Background: Type 2 diabetes (T2D) is a chronic, progressive disease. Caloric re-
striction and subsequent weight loss have been associated with both improvements
and, in some cases, remission of T2D.
Aim: To systematically review the safety and effectiveness of calorie‐restricted
diets on weight change and the remission of T2D.
Methods: Electronic databases were searched. Intervention trials including a calorie
restriction, published between 2010 and 2020, evaluating the remission of T2D
(HbA1c <6.5% without diabetes medication) were selected. Risk of bias was
assessed.
Results: Eight trials met inclusion criteria including four randomized controlled and
four single‐arm trials. Three controlled trials found greater remission in the calorie‐
restricted arm (p < 0.05). A recent diagnosis of diabetes was associated with higher
remission rates (75%–80%) with an inverse association between duration of dia-
betes and rate of remission (r = −0.94). A higher level of remission was observed
with greater calorie restriction in non‐new diagnosis studies. Greater weight loss
was associated with increasing rates of remission (r = 0.83). No reported adverse
events led to withdrawal from trials. There was great heterogeneity in study design.
Conclusion: Remission rate of T2D achieved through calorie restriction is high and
similar to that reported in the bariatric surgery literature. Remission should be the
aim at diagnosis and calorie restriction could be used to achieve this. The target
weight loss should be >10% body weight in people with obesity. More research is
needed into the optimum level of calorie restriction and the support required for
long‐term remission. National guidelines should be updated to reflect recent
evidence.
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1 | INTRODUCTION
The prevalence of type 2 diabetes (T2D) has increased over the past
20 years with global prevalence rates (in people aged 20–79 years)
reaching 9.3% in 2019.1 A more recent concern is that T2D is a risk
factor for a worse outcome in those with COVID‐19 infection. The
mortality rate for those with diabetes or uncontrolled hyperglycemia
was found to be more than four times higher than for those without
either of those risk factors.2 People with T2D have been found to
have significantly higher risk of respiratory distress syndrome and
multiple organ injury.3,4 The economic costs of T2D are increasing as
well as the immeasurable pain and suffering of those with the con-
dition.5–8
The national guidance on the management of T2D mentions a
few sentences about dietary advice, with the bulk of the information
relating to medications and algorithms to progress through when
treating worsening hyperglycemia.9 The aim of remission of diabetes
is not specifically discussed anywhere in this guideline. Eligibility for
bariatric surgery is discussed in the national guidelines for obesity
management for those with new‐onset T2D with a body mass index
(BMI) greater than 30 or at a lower BMI if people are of Asian
origin.10 The 7‐year cumulative incidence of achieving partial/com-
plete or prolonged remission in people newly diagnosed with T2D on
no diabetic medication with standard care was 1.60%.11
A recent review by Hallberg et al.12 examined reversal of dia-
betes by three methods: bariatric surgery, carbohydrate‐restricted
diets, and low‐calorie diets. There have been a number of system-
atic reviews in the field of bariatric surgery13,14 and carbohydrate
restriction15,16 for the treatment of T2D. Kelly and colleagues17
conducted a review of studies that examined lifestyle modifications
targeting the remission of T2D. However, their definition of remis-
sion was broad and included normalization of fasting plasma glucose,
HbA1c, an oral glucose tolerance test and normalization of β cell
function. Taylor18 summarized the rationale for the DiRECT study,
but the article did not systematically review all the published evi-
dence in the field of energy restriction and diabetes remission.
Lim et al.19 demonstrated that insulin resistance and pancreatic
β‐cell failure could be reversed with an energy‐restricted diet (600
kcal/day). There was an associated decrease in liver and pancreatic
triacylglycerol stores. Steven et al.20 demonstrated that an 8‐week
energy‐restricted diet (624–700 kcal/day) produced a sustainable
normalization of fasting plasma glucose to less than 7.0 mmol/L in
40% of the study population at 6 months. Responders were noted to
have a shorter duration of diabetes (3.8 ± 1.0 vs. 9.8 ± 1.6 years,
p = 0.007).
There has been much debate about the definition of reversal and
remission of T2DM. Buse et al.21 suggested a partial remission to be
defined as an HbA1c less than 6.5% and fasting glucose of 5.6–6.9
mmol/L for at least 1‐year duration without pharmacological therapy.
Complete remission was defined as having HbA1c in the normal
range and fasting glucose less than 5.6 mmol/L for 1 year without
pharmacological therapy. A simpler HbA1c criteria based on the
American diabetes guidelines of diagnosis of diabetes with remission
if HbA1c <5.7% and improvement with HbA1c 5.7%–6.5% with no
hypoglycemic medication and a duration of at least 1 year has also
been proposed.22 Some authors12 have removed metformin from the
list of medications for glycemic control as this drug has a role in
prevention.23 For the purposes of this review, as some studies
included were of short duration and there is such heterogeneity of
definition of remission between studies, a complete or partial
remission was defined as an HbA1c less than 6.5%/48 mmol/mol
without the use of diabetes medication.
The aim of this review was to assess the safety and effec-
tiveness of energy‐restricted interventions in achieving remission
of T2D. Scalable interventions for the remission of T2D are
urgently needed and there has been no in‐depth review of energy
restriction conducted for this purpose with a uniform definition of
remission. The primary outcome measure was levels of HbA1c less
than 6.5%/48 mmol/mol with no hypoglycemic medications in
energy‐restricted dietary interventions. Secondary outcome mea-
sures were weight change, reduction in HbA1c levels, and serious
adverse events.
2 | METHOD
A literature search was conducted using the electronic databases of
PubMED and Wiley Online. The following search terms were used:
#1: “Diabetes” OR “Diabetes Mellitus” OR “Type 2 Diabetes” OR
“Non Insulin Dependent Diabetes” OR “T2DM” or “NIDDM”; #2:
“Calorie restricted” OR “Very low calorie diet” OR “Lifestyle inter-
vention” OR “Intensive Lifestyle”; #3: “Remission” or “Reversal”.
An advanced electronic search was performed and filters were
applied to include only journal articles, publications in the English
language, species to be human only, adults and searches were limited
to the last 10 years. The final search was conducted on 30 January
2021. The reference lists of relevant publications were hand
searched to find any relevant articles. The titles and abstracts were
screened against the inclusion and exclusion criteria listed in Table 1.
Full‐text articles of the short‐listed articles were then further
screened. Inter‐library loans were undertaken when necessary to
locate full text articles. A second reviewer independently assessed
papers for final eligibility and any disagreement was discussed and
resolved.
Data were extracted by a single reviewer. The data included
author, year, country of origin, duration of study, number of partic-
ipants, male/female ratio, number of completers of each arm of trial,
baseline weight, baseline HbA1c%/mmol/mol, mean duration since
diagnosis (unless stated as median), inclusion criteria, intervention
and control details, outcome measures of interest and serious
adverse events. HbA1c % and mmol/mol were converted where
possible, so both could be presented. Mean weight loss and standard
deviation and mean change in HbA1c % were calculated from sup-
plementary information for one study.24 The Pearson correlation
coefficient (r‐value) was calculated for a number of variables in the
collated results.
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The study was reported according to PRISMA statement25 (see
Figure S1). All supplementary tables are available by contacting the
corresponding author.
The Downs and Black26 quality assessment tool was used to
assess the risk of bias. This tool was chosen as it can be used to
compare randomized and non‐randomized controlled trials.
3 | RESULTS
Preliminary searches found a paucity of randomized controlled trials
in this field in the last 10 years, so the decision was made to include
single‐arm intervention trials even though they would be at higher
risk of bias, to increase the breadth of data to analyze. The literature
search generated 660 results. After removal of duplicates, 641 re-
cords were screened. Seventeen studies were assessed and finally
eight studies were included (see Figure 1). The assessment of bias has
been summarized in Table S1, with original scoring in Table S2.
Four publications of randomized controlled trials were found
including a 2‐year update for one of the studies. Two of these were
retrospective analyses of data. Four single‐arm studies were also
included. The total sample size from all of the eight studies was 5764
participants. Energy restriction ranged from prescribed periods of
600 kcal/day to individualized levels between 1200 and 1800 kcal/
day for the entire study duration. The length of time since diagnosis
ranged from new diagnosis to 5 years. The studies took place in the
United Kingdom, India, United States, Denmark, Thailand, and Qatar.
Detailed characteristics including interventions and controls (if
applicable) for all studies have been described in Table 2.
3.1 | Diabetes remission rates
Lean et al.27 conducted a clustered randomized controlled trial to
assess if intensive management of weight through 3–5 months of
total diet replacement (825–853 kcal/day) and stepped food re‐
introduction could lead to remission of diabetes in a primary care
setting (the DiRECT trial). Initial results were presented at 1 year27
and achieved a weight loss of 10 kg in the intervention group
compared with 1.0 kg in the control group (p < 0.001). In the second
year of the study,28 weight gain was treated with titrated meal
replacements depending on if the gain was more than 2 or 4 kg. At
this point, the weight loss was 7.6 kg in the intervention group
compared with 2.3 kg in the control group (p < 0.001). Strengths of
the study include the number of participants included (n = 298), the
duration of follow‐up (24 months), and the real‐world setting, so the
results could be translated to community populations with T2D.
Limitations of the study include the lack of blinding of participants
and assessors (although difficult to achieve with any dietary inter-
vention and this risk of bias applies to all included studies). Partici-
pants receiving insulin were excluded, and this is an important
TAB L E 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Publication date 2010–2020 <2010
Language English Non‐English
Study design Randomized controlled trial or intervention study Cohort, crossover, case–control trial
Population Adults ≥18 years of age, diagnosis of type 2 diabetes,
any duration of diagnosis, any medication regime
Children, animal studies, pre‐diabetes, type 1
diabetes, MODY, non‐diabetes
Intervention Energy‐restricted dietary intervention Drug‐based intervention beyond standard care,
bariatric surgery, carbohydrate restriction
Control group Standard care if control present Bariatric surgery
Primary outcome HbA1c <6.5% without diabetes medication Lipid profiles, blood pressure, body mass index, lean
mass, changes in medication, quality of life
Secondary outcome Weight change (kg) and glycemic control (HbA1c%)
with both factors clearly related to dietary changes
in a multi‐component intervention.
Study duration Any duration
F I GUR E 1 Remission rate compared with weight loss
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subpopulation, for whom it is important to quantitate the possibility
of remission. The definition of remission was HbA1c <6.5% off
medications for at least 2 months which is a shorter duration than
the standard of 1 year used in many studies which potentially pro-
duced a higher remission rate. The study population was of homog-
enous ethnicity with 98% being white in the intervention arm and
99% in the control arm. The authors commented that the results may
not be able to be extrapolated to a South Asian population. They
noted that as de‐prescribing of diabetic medication is not part of
standard guidelines, it is possible that a higher proportion of the
control group may have achieved remission if this was done. The
authors found a remission rate of diabetes of 46% in the intervention
group compared with 4% in the control group at 1 year (p < 0.001).
At 2 years, remission rates in the intervention group were 35.6% and
3.4% in the control group (p < 0.0001).
The DIADEM‐1 study, presented by Taheri et al.36 was a ran-
domized controlled trial comparing an intensive lifestyle intervention
to standard care. The cohort was younger than the DiRECT study
(age 18–50), had a shorter duration of diabetes (less than 3 years),
and there was a male preponderance (73%). Total dietary replace-
ment of 800–820 kcal/day for 12 weeks followed by a phased food
re‐introduction and increased physical activity resulted in weight loss
of 12.0 kg in the intervention group compared with 4.0 kg in the
control group (p < 0.0001). Strengths of the study include the num-
ber of participants (n = 147), the duration of the study (12 months),
and the inclusion of patients taking insulin who had been excluded
from the DiRECT trial. A limitation noted by the author was that the
intervention was delivered by a multidisciplinary team that may not
be available in other health settings. The remission rate was 61% in
the intervention group at 12 months compared to 12% in the control
group (odds ratio 12.03 [95% CI 5.17–28.03], p < 0.0001).
Reid‐Larsen et al.32 performed a secondary analysis of a ran-
domized controlled trial33 examining the effect of energy restriction
for 4 months (amount unspecified) and supervised exercise for gly-
cemic control compared with standard care. In this analysis, the
primary outcome was partial or complete remission of T2D. Weight
loss at 2 years was 1.4 kg in the intervention group and 0.8 kg in the
control group (p = 0.17). Strengths of this study include the number
of participants (n = 98) and length of follow‐up. The trial was well
conducted and the participants represented the source population.
Weaknesses include the energy restriction only occurring for the first
4 months of the study and the location of much of the delivery being
a teaching hospital which may not be representative of the care that
the average patient with T2D is able to access. Also, the secondary
analysis was not powered to assess T2D remission rates. Remission
rates in this study were larger at 23% for the intervention group than
7% for the control group, but the difference was not statistically
significant (p = 0.08).
A retrospective analysis was conducted using the results of the
Look AHEAD trial.30,31 The trial lasted 4 years. Energy restriction
ranged from 1200 to 1800 kcal/day in the intervention group and
meal replacements were offered. Physical activity was increased to
175 min/week. Weight loss at year 1 was 8.6% in the intervention
group compared to 0.7% in the control group (p < 0.001). In year 4,
weight loss was 4.7% in the intervention group compared with 0.8%
in the control group (<0.001). Strengths of the study again include
the number of participants (n = 5145) and the duration of the
study. This was also an innovative and pivotal study in reframing
T2D from a chronic progressive condition to one with a possibility
of remission. The analysis excluded participants who underwent
bariatric surgery. However, they also excluded participants with
missing outcome data allowing for potential attrition bias. The pa-
tients were extensively screened for their potential to lose weight,
meaning the results may not be applicable to the general population
with T2D. Also, as it was a retrospective analysis, a power calcu-
lation was not done. At year 1, 11.5% in the intervention group
compared to 2% in the control group achieved remission
(p < 0.001). At year 4, this was 7.3% in the intervention group and
2% in the control group (p < 0.001).
A single‐arm study to assess the efficacy, safety, and durability of
a very‐low‐calorie diet (VLCD) in Thai patients for the remission of
T2D was undertaken by Umphonsathien and colleagues.35 The
authors recruited members of staff at a hospital. The intervention
involved a run‐in of 2 weeks of total diet replacement of 600 kcal/day
to assess compliance. If this was tolerated, it was followed by 8 weeks
of 600 kcal/day, then a stepwise calorie increase with week 9—800
kcal/day, week 10—1000 kcal/day, week 11 —1200 kcal/day, and
week 12—1500 kcal/day. Mean weight loss of 9.5 kg was achieved in
the study group at 14 weeks. Strengths include the clear outcomes
and aims of the study and that a power calculation was done.
Weaknesses include the small sample size (n = 20), no control group,
the recruitment of hospital staff who may not be representative of
the typical population with T2D and participants’ level of compliance
was unclear. Rates of remission were 75% at 14 weeks, and fell to
30% and 6 months and 20% at 1 year.
A 6‐month single‐arm study was undertaken in participants with
newly diagnosed diabetes to assess the effect of a program including
a 500 kcal/day deficit and exercise (walking) on the rate of remis-
sion.34 Mean weight loss at 6 months was 9.7 kg in the participants.
Strengths of this study by Ades et al. include the follow‐up time (6
months) and the clear aims and methods reported. Weaknesses
include the fact that there was no control arm, it is unclear how
participants were recruited and there were a small number of par-
ticipants (n = 12). The rate of remission was very high at 80%. There
is, however, no longer term follow‐up to assess how participants
fared once the intervention was complete.
Sarathi et al.29 conducted a single‐arm study on young adults
with newly diagnosed T2D to assess the reversibility of the condition.
Calorie intake was limited to 1500 kcal/day and participants under-
took 1 h of brisk walking daily. Mean weight loss was 6.6 kg at 1 year
and 7.7 kg at 2 years. Strengths include clear aims and interventions
of the study. Weaknesses include the small sample size (n = 32), a
lack of control arm, no power calculation, and the recruitment pro-
cess was unclear. Therefore, the adults recruited may not be typical
of the population with T2D. The remission rate at 1 year was 75%
and at 2 years 68.8%. This is an impressive maintenance rate of
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remission. The calorie restriction (1500 kcal) was not as low as the
DiRECT study or Umphonsathien et al.35
Bhatt et al.24 conducted a single‐arm study on the use of 1000
kcal/day total diet replacements for 12 weeks. Moderate aerobic and
resistance intensity exercise was advised from week 2. Mean weight
loss at 12 weeks was 6.8 kg. This was a poorly conducted and
reported study. There were no clearly described aims and outcomes.
There was no control arm and the sample size was small (n = 12). It
was unclear how participants were recruited. Fifty percent of
participants achieved remission of diabetes at 12 weeks.
3.2 | Intensity of weight loss intervention
Three factors varied in the intensity of the intervention: the level of
calorie restriction, the duration of calorie restriction, and the addition
of supervisedstructuredphysical activity.Acomparisonof the intensity
of the intervention is tabulated in Table S4. An average adult's calorie
intake is assumed to be 2250 kcal/day (males 2500 kcal and females
2000 kcal),37 the calorie deficit has been calculated as the difference
between average calorie intake and the calorie intake of the inter-
vention. This is not accounting for cultural differences in calorie intake
or the number of males and females in each study.
One of the most intense calorie restrictions was in the DiRECT
study,27,28 but there was also a maintenance plan beyond the first
intervention. Of note, weight losses had decreased on average by
year 2 from −10.0 to −7.6 kg. The DIADEM‐1 study36 combined a
strict calorie restriction with physical exercise and achieved the
highest total weight loss at the end of a study. Umphonsathien et al.35
had the most severe calorie restriction but there was no intervention
beyond 14 weeks and weight loss results were not collected beyond
this. There were relatively low calorie restrictions by Ades et al.34
and Sarathi et al.29 but impressive weight losses. There were ongoing
weight losses in the second year for Sarathi et al.29 Both these
studies used physical activity raising the possibility of its importance
in remission maintenance. However, contradictory to this hypothesis
is that Ried‐Larsen et al.32 used structured exercise as part of the
intervention with minimal weight loss and a non‐statistically signifi-
cant reduction in remission in the control group. The calorie re-
striction only lasted 4 months in this study, and it is possible that this
was not a strong enough intervention. The optimum balance of
caloric restriction and exercise for diabetes remission and mainte-
nance is an important question that needs further assessment.
Weight loss was expressed as a percentage by Gregg et al.30 so it is
difficult to directly compare with the other studies.
3.3 | Remission rates compared with weight loss
Figure 1 shows weight loss in kilograms plotted against remission
rates for the intervention groups as well as the control groups. Gregg
et al.30 was excluded from this as weight loss was presented in
percentage terms. Increased weight loss appears to be associated
with increased rates of remission (r = 0.83). The largest mean weight
losses were made by Lean et al.27 in year 1 at 10 kg, Taheri et al.36 in
year 1 at 12.0 kg, Ades et al.34 at 9.7 kg at just 6 months, and
Umphonsathien et al.35 at just 14 weeks with 9.5 kg. The remission
rate fell rapidly over the first year for Umphonsathien et al.35 and by
just over 10% for Lean et al.28 Lean et al.27 found that the odds ratio
per kilogram weight loss for attaining remission was 1.32 (95% CI:
1.23– .41; P < 0.0001). Gregg et al.30 found that the probability of
1‐year remission was the highest among those who lost greater than
6.5% weight (16.4%; 95% CI: 14.5%–18.6%). Remission of diabetes
was possible for 70% of those who maintained more than 15 kg
weight loss in the DiRECT study27; however, only 24% was able to
achieve this weight loss in the first year despite a severe calorie
restriction. Sarathi et al.29 found that no patients who achieved
remission and maintained or decreased from their 3‐month weight
loss had recurrence of T2D. Gregg et al.30 found that one‐third of
those who had a remission returned to diabetes every year. The
associated weight gain was not reported.
3.4 | Change in HbA1c levels
This data is presented in Table S5. The studies with higher baseline
HbA1c level had a greater fall (Sarathi et al.29 and Bhatt et al.24). Gregg
et al.30 did not present data on changes in HbA1c levels. Interestingly,
Ried‐Larsen et al.32 found an increase in HbA1c level in both the
intervention andcontrol groups at 24months. The12‐monthdata from
this study,33 showed a change of−0.31% in the intervention group and
−0.08% in the control group (p = 0.15). As some patients developed
remission, presumably in those that did not, there was an overall in-
crease in HbA1c to account for this mean rise in each arm.
There is no clear association between baseline HbA1c levels and
remission rate (r = 0.36) (Figure S2). Gregg et al.30 found an associ-
ation between low baseline HbA1c levels and remission rates
(p < 0.001). Umphonsathien et al.35 and Sarathi et al.29 found no
association between baseline HbA1c and remission rates. Of note,
Ried‐Larsen et al.32 and Taheri et al.36 had particularly low levels of
baseline HbA1c in the intervention and control groups. This may
explain the relatively low levels of mean weight loss achieving better
remission rates in these control groups (7% and 12%) compared with
the control groups in the other studies. This may also have contrib-
uted to the lack of statistical significance between the intervention
and control groups for Ried‐Larsen et al.32
3.5 | Remission compared to and baseline weight
and duration of diabetes
Figures S3 and 2 have been plotted to show rates of remission in the
intervention arm against baseline weight and duration of diabetes
Only the first remission rate recorded (which was the highest rate in
all studies) has been plotted to examine the relationship between the
maximal remission potential and the other variables. There is no clear
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association between baseline weight and remission rates (r = −0.43).
Ethnically, populations such as Thai may have lower mean body
weights. Lean et al.28 found no association between baseline BMI and
likelihood of remission at 24 months. Umphonsathien et al.35 and
Sarathi et al.29 found no association between baseline weight and
remission rates. However, Gregg et al.30 did find an association with
lower BMI and likelihood of further remission (p < 0.001).
Figure 2 shows an inverse association between the duration of
diabetes and the remission rate (r = −0.94). The duration of diabetes
was a mean value for all studies, except Umphonsathien et al.35
Gregg et al.30 and Bhatt et al.24 who presented median values. The
studies with the longest duration since diagnosis were Gregg et al.30
and Ried‐Larsen et al.32 This may have contributed to the lower
remission rates in both of these studies. There was no association
between the duration of diabetes within 6 years from diagnosis
inclusion criteria in the DiRECT study. However, Figure 2 shows the
highest rates of remission were achieved in those newly diagnosed
and the mean time since diagnosis was 3 years for both arms of the
DiRECT study. Both studies with participants having newly diagnosed
diabetes (Sarathi et al.29; Ades et al.34) were single‐arm studies with
evidence of bias (Table S2). Gregg et al.30 found a statistically sig-
nificant association between fewer years since diagnosis and remis-
sion rates (p < 0.001). Bhatt et al.24 found that responders had a
shorter duration of diabetes than non‐responders (1.5 vs. 4.0 years),
but no statistical analysis was carried out. In contrast, Umphonsa-
thien et al.35 found no association between diabetes duration and
remission rates.
3.6 | Adverse events
Taheri et al.36 found fewer serious adverse events in the intervention
arm compared to the control arm as did Lean et al.28 who also re-
ported statistical significance with p = 0.029 (see Table 3). ThereF I GUR E 2 Remission rate compared with duration of diabetes
TAB L E 3 Serious adverse events
Author, Year
Serious adverse events
Lifestyle/Reduced calorie diet arm (n) Control (n) p‐Value
Lean et al.27 n = 7
Two events in the same patient thought to
be related to intervention—biliary colic
and abdominal pain. Others were brief
overnight admissions for unrelated
investigations/events. None led to
withdrawal from the trial.
n = 2







Lean et al., 2019)
Lean et al.28
Year 2 results
n = 9 events in 6 participants
One non‐fatal MI in a patient that did not
attend for review. None led to
withdrawal from the trial.
n = 22 events in 16 participants




Bhatt et al.24 Not described.
Sarathi et al.29 Not described.





n = 0 1.00
Ades et al.34 Not described
Umphonsathien et al.35 n = 0
Taheri et al.36 n = 0 n = 55 events in 4 participants
4 admissions to hospitals for
unexpected event—
supraventricular tachycardia,
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were no significant differences in adverse events between the two
groups reported by Gregg et al.30 Bhatt et al.24 Sarathi et al.29 and
Ades et al.34 did not describe adverse events. Umphonsathien et al.35
had no adverse events and Reid‐Larsen et al.32 had one serious
adverse event in the intervention group (an episode of atrial fibril-
lation), but this was not statistically significant (p = 1.00). There were
few adverse events described that related to the interventions and
none that led to withdrawal from the studies.
4 | DISCUSSION
This review has found that dietary energy restriction is an effective
treatment strategy for the remission of T2D with higher rates
associated with increased weight loss (r = 0.83), decreased time from
diagnosis (r = −0.94), and increased intensity of intervention
(in terms of level and duration of calorie restriction) in studies where
diagnosis was not recent. However, the durability of extreme calorie
restriction beyond 2 years still needs to be established. The highest
remission rates involved patients with a new diagnosis of T2D
although these studies had a high level of bias. Five studies presented
remission data at 1 year and the remission rate varied between
11.5% and 75%.27,29,30,35,36 Energy restriction as a method of dia-
betes reversal has also been found to be safe with relatively few
serious adverse events reported.
Bariatric surgery has been recommended as a treatment for
people with T2D and a BMI of 30 kg/m2 or above, or at a lower level
if of Asian origin and not achieving treatment targets.38 Much of the
published research has compared surgery to intensive weight man-
agement. Parikh et al.39 found superior rates of remission with sur-
gery (65%) compared with medical weight management (0%) at 6
months (p < 0.0001). Medical weight management included tailored
counselling on diet, exercise and adjustment of diabetic medications.
Cummings et al.40 compared Roux‐en‐Y gastric bypass with an
intensive lifestyle and medical intervention and found 60% remission
rates in the surgery arm and 5.9% in the medical arm at 1 year. The
intensive lifestyle arm in this study included dietary advice, exercise
five times a week, and diabetic pharmaceutical treatment in keeping
with current guidelines. Courcoulas et al.41 found that Roux‐en‐Y
gastric bypass was superior (50%) to a laparoscopic gastric band
(27.3%) and an intensive lifestyle weight loss intervention (0%) at 1
year. Courcoulas et al.41 reported that the medical intervention was
based on the Look AHEAD trial, but the remission rate was much
lower than that reported by Gregg et al.30 Parikh et al.39 mentioned
themselves that they could have integrated more extensive lifestyle
changes into the medical weight management arm.
A 7‐year multicenter longitudinal study42 found that the rate of
remission was 60.2% for Roux‐en‐Y gastric bypass and 20.3% for
laparoscopic gastric banding in patients with T2D. The authors re-
ported that lifestyle programs are often the first‐line recommenda-
tions for obesity management, but are largely ineffective and when
successful, weight loss is rarely sustained. However, the outcomes in
the lifestyle arms of bariatric surgery are much below those of studies
primarily focused on remission of diabetes through caloric restriction
in this review. This suggests the intensity of caloric‐restriction inter-
vention may be too low in these bariatric trials. The outcomes in many
of the calorie‐restricted studies in this review were comparable to the
remission rates achieved by bariatric surgery.
Carbohydrate restriction has also been used as a treatment for
T2D, but meta‐analysis has shown little effect on glycemic control
beyond the short term.43 However, a more recent study44 compared
a low‐carbohydrate diet (moderate protein, fat to satiety, and no
energy restriction), that aimed for ketosis with usual care in T2D and
60% of completers achieved an HbA1c below 6.5% without diabetic
medication (excluding metformin) at 1 year. At 2 years, 54% of
completers had an HbA1c below 6.5% with no diabetic medication
except metformin.45 Therefore, it is clear that further routes of
diabetes remission beyond bariatric surgery are emerging.
National guidance9 briefly mentions lifestyle changes as advice
that should be offered to patients, with the focus of the guideline being
on an algorithm of increasing medication. All the studies examined in
this review have found low levels of remission with standard care.
Dambha‐Miller et al.46 conducted a 5‐year prospective cohort
study including 867 participantswith newly diagnosed T2D. Remission
was achieved in 30%at 5‐year follow‐upof the pooled data and the risk
ratio was significantly higher in those that achieved ≥10% weight loss
(in years 1–5), than those that maintained the same weight (risk ratio
2.43 [95% CI: 1.78–3.31; p < 0.01]). The remissions in this study were
achievedwithout extreme calorie restriction or lifestyle interventions.
Ten percent weight loss seems a reasonable initial target for remission
of diabetes and was theminimumweight loss that resulted large levels
of remission in a number of studies.27–29,34–36 In fact, in the DiRECT
studywith a baselineweight of approximately 100 kg in both groups, of
those losing greater than 10 kg, 64% achieved remission at 24months.
For 5–10 kg, it was 29%, and for less than 5 kg, it was 5% remission.
Remission was more likely with greater weight loss from baseline with
adjusted odds ratio 1.2 per kg loss. The most impressive remissions in
the current review were achieved by Sarathi et al.29 and Ades et al.34
who both conducted studies on patients with newly diagnosed
diabetes. The calorie restrictions in both studies were relatively low,
but perhaps more easily maintained.
Kelly and colleagues17 found that when they classified lifestyle
interventions into therapeutic (600–1500 kcal total daily intake), the
weighted mean remission was 49.4% versus subtherapeutic (800–
1500 kcal total daily intake), where the weighted mean remission was
6.9%. The distinction between therapeutic and subtherapeutic dosing
was based on treatment goals and whether the intervention pro-
duced remission in a substantial proportion of participants. There is
clearly an overlap in calorie intake in both groups. They did not
examine the relationship between time from diagnosis of T2D with
remission rates. The authors noted that the dosing intensity required
to achieve remission of T2D was much higher than that required to
prevent it. It is therefore plausible that a lower intensity intervention
may be adequate to achieve remission earlier in the pathogenesis of
the disease (i.e., at diagnosis) where there is less β cell damage. In an
era of COVID‐19 infection where the risk of diabetes is even greater
JACOB AND AVERY - 11
than previously thought, would the information that a new diagnosis
of diabetes is likely reversible for a limited number of years be the
motivating factor to help patients lose and maintain weight loss? This
is an interesting area for future research.
Lean et al.27 noted that medication withdrawal is not part of
standard guidelines which may have led to the rate of remission
being under‐reported in their control group. If 30% of patients with
newly diagnosed diabetes are achieving remission without intensive
interventions,46 and many first and second intensification medica-
tions lead to weight gain, perhaps national guidelines should include
instructions for formal de‐prescribing, to aid those who are managing
to lose weight to maintain remission.
Strengths of this review include the fact that there have been few
reviews in this developing area of research. There were limitations of
time and resources and the review would have benefited from wider
searches of grey literature and unpublished research. Also, the results
would have benefited from the calculation of meta‐analysis of odds
ratios to quantify associations and calculate the statistical significance
if more resources were available. A paucity of well‐constructed
randomized controlled trials in this developing area of research
meant that a small number of single‐arm studies were included which
may increase the risk of bias in the results and conclusions.
There was great heterogeneity in the definition of remission in
the studies but a pragmatic definition of any duration of HbA1c
<6.5%/48 mmol/mol without medication was used for the purposes
of this review. This would have led to bias as studies that only
measured remission at 1 year may be underreporting maximal
remission rates at any time point.
5 | CONCLUSION
Recommendations for practice based on the findings of this review
are to offer patients with a diagnosis of diabetes within the last 6
years an opportunity to achieve remission. The target weight loss
should be at least 10% of body weight in individuals with sufficient
overweight and obesity. The high levels of remission of newly diag-
nosed diabetes were a surprising finding, as this was not reported in
the highly publicized DiRECT trial. Therefore, weight loss should be
particularly encouraged as a first‐line approach for those with a new
diagnosis of T2D. The favored method should reflect patient pref-
erences, but options should include an energy‐restricted diet. Total
meal replacement methods have been very effective in a number of
studies in achieving this in the short and medium terms, but are not
the exclusive route to remission. More research is needed to estab-
lish the optimal intensity in terms of energy restriction and duration,
and the role of exercise for the maintenance of remission. National
guidelines should be updated to reflect recent evidence.
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